<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015925</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068574, J0253</org_study_id>
    <secondary_id>U01CA069854</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0253</secondary_id>
    <secondary_id>MSGCC-0050</secondary_id>
    <secondary_id>NCI-2791</secondary_id>
    <nct_id>NCT00015925</nct_id>
  </id_info>
  <brief_title>MS-275 in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Phase I Clinical-Labratory Study of the Histone Deacetylase (HDA) Inhibitor MS-275 in Adults With Refractory and Relapsed Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have&#xD;
      hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxic effects and pharmacokinetics of MS-275 in patients with poor-risk&#xD;
           hematologic malignancy.&#xD;
&#xD;
        -  Determine whether this drug induces changes in hematologic differentiation, in terms of&#xD;
           changes in morphology, cell surface marker expression, and acetylation status, in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine whether this drug induces clinical response in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral MS-275 on days 1, 8, 15, and 22. Courses repeat every 6 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of MS-275 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entinostat</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following histologically confirmed diagnoses:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)&#xD;
&#xD;
                    -  Newly diagnosed de novo AML in patients over 60 years old with the following&#xD;
                       poor-risk features:&#xD;
&#xD;
                         -  Antecedent hematologic disorder&#xD;
&#xD;
                         -  Complex karyotype or other adverse cytogenetics&#xD;
&#xD;
                         -  Stem cell immunophenotype&#xD;
&#xD;
                    -  AML arising from myelodysplastic syndromes (MDS)&#xD;
&#xD;
                    -  Secondary AML&#xD;
&#xD;
                    -  Relapsed or refractory AML, including primary induction failure&#xD;
&#xD;
               -  MDS&#xD;
&#xD;
                    -  Poor-risk, defined as the following:&#xD;
&#xD;
                         -  International Performance Score at least 1.5&#xD;
&#xD;
                         -  More than 10% marrow blasts&#xD;
&#xD;
                         -  Cytopenias in at least 2 lineages&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
                    -  Newly diagnosed de novo ALL in patients over 60 years old with the following&#xD;
                       poor-risk features:&#xD;
&#xD;
                         -  Complex karyotype or other adverse cytogenetics&#xD;
&#xD;
                         -  Mixed lineage immunophenotype&#xD;
&#xD;
                    -  Relapsed or refractory ALL, including primary induction failure&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
                    -  CML in accelerated phase or blast crisis&#xD;
&#xD;
                    -  Interferon-refractory CML in chronic phase&#xD;
&#xD;
               -  Multiple myeloma (MM)&#xD;
&#xD;
                    -  Relapsed or refractory, including prior autologous stem cell transplantation&#xD;
&#xD;
               -  Acute promyelocytic leukemia&#xD;
&#xD;
                    -  Prior treatment with tretinoin&#xD;
&#xD;
                    -  Ineligible for arsenic trioxide&#xD;
&#xD;
                    -  No evidence of active coagulopathy&#xD;
&#xD;
                    -  Low-risk for developing clinically significant coagulopathy during study&#xD;
&#xD;
                         -  Low tumor burden by marrow aspiration at time of relapse&#xD;
&#xD;
                         -  No prior coagulation-related sequelae (deep vein thrombosis, pulmonary&#xD;
                            embolism, or CNS thrombosis or bleed)&#xD;
&#xD;
          -  Failure after primary induction therapy or relapse after complete remission allowed if&#xD;
             patient received no more than 3 courses of prior induction/reinduction therapy&#xD;
&#xD;
          -  Not eligible for curative stem cell transplantation&#xD;
&#xD;
          -  No hyperleukocytosis with at least 50,000/mm^3 leukemic blasts&#xD;
&#xD;
          -  No active CNS leukemia&#xD;
&#xD;
          -  No plasma cell leukemia&#xD;
&#xD;
          -  No amyloidosis resulting in major organ dysfunction&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No disseminated intravascular coagulation&#xD;
&#xD;
          -  No hyperviscosity&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST/ALT no greater than 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
          -  No uncorrected hypercalcemia&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  LVEF at least 45% by MUGA or echocardiogram&#xD;
&#xD;
          -  No intrinsic impaired cardiac function, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 3 months&#xD;
&#xD;
               -  Prior severe coronary artery disease&#xD;
&#xD;
               -  Cardiomyopathy&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior growth factors (epoetin alfa, filgrastim [G-CSF],&#xD;
             sargramostim [GM-CSF], interleukin [IL]-3, or IL-11)&#xD;
&#xD;
          -  At least 4 weeks since prior autologous stem cell transplantation&#xD;
&#xD;
          -  No prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  At least 24 hours since prior hydroxyurea or mercaptopurine for prevention of&#xD;
             leukostasis&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior emergency radiotherapy to large soft tissue or lytic bony&#xD;
             lesions for MM&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 24 hours since other prior noncytotoxic agents for prevention of leukostasis&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith E. Karp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

